About Us - Founder's Message in 2026 (In English)

[Notice of MediRedox]

Opening a New Horizon in APE1/Ref-1-Based Diagnostics and Therapeutics

Welcome to MediRedox.

Since taking my first steps into APE1/Ref-1 protein research, my goal over the past two decades has been to elucidate the complex biological functions of this protein. Notably, in 2013, we made the world's first discovery that APE1/Ref-1—previously thought to exist solely within cells—is secreted into the bloodstream, successfully proving its utility as a biomarker for disease diagnosis. This pioneering basic research into redox signaling, inflammatory mechanisms, and the fight against intractable cancers has now evolved into MediRedox, a company providing practical clinical solutions. Today, we have firmly established ourselves as a global helper driving research and innovation in the APE1/Ref-1 field.

We understand that true medical innovation stems from absolute precision. This is exactly why we developed our own proprietary detection methods, high-sensitivity ELISA kits, and recombinant proteins. 

Today, I am proud to say that our proprietary products have served as the core driving force behind numerous studies published in world-renowned, top-tier academic journals, including Free Radical Biology and Medicine. 

MediRedox will serve as a strong bridge connecting cutting-edge molecular basic research with clinical treatments that save patients' lives. Currently, we are dedicating our utmost efforts beyond the commercialization of innovative diagnostic technologies, focusing aggressively on the development of novel therapeutic technologies that directly target APE1/Ref-1. However, this monumental goal of overcoming intractable cancers and severe diseases cannot be achieved by our efforts alone. Now more than ever, close collaboration and joint research with outstanding researchers and partner institutions.

If you are seeking definitive diagnostic biomarkers and innovative therapeutic targets to overcome the intractable cancers and severe inflammatory diseases, please join us. We invite you to this journey of innovation alongside the global standard in APE1/Ref-1 research.

Thank you for your continued trust and partnership.

Byeong Hwa Jeon CEO / Professor, MediRedox